Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin.
Talha BadarMehdi HamadaniVeronika BachanovaKami J MaddocksElvira UmyarovaJulio C ChavezNarendranath EpperlaSaurabh ChhabraAna C XavierReem KarmaliMohammed SalhabNishitha ReddyMartha J GlennFrancisco J Hernandez-IlizaliturriChristopher R FlowersAndrew M EvensZheng ZhouFrederick LansiganStefan K BartaJonathon B CohenTimothy S FenskeLuciano J CostaPublished in: Leukemia & lymphoma (2018)
We evaluated outcome of 235 primary treatment failure (PTF) diffuse large B-cell lymphoma (DLBCL) patients based on salvage chemotherapy regimen and putative cell-of-origin (COO). Patients were divided into two groups; group A (n = 38) received high-dose cytarabine containing regimen, either DHAP or ESHAP. Patients in group B (n = 197) received ifosfamide, carboplatin, and etoposide (ICE) +/- rituximab. No difference in overall response rates (CR + PR) was observed based on salvage chemotherapy regimen and COO. After adjustment for the presence of ultra high-risk features, overall survival of germinal center B-cell like (GCB) DLBCL patients in group A was not significantly different from survival in group B (HR 0.86, 95% CI 0.46-1.60, p = .64). Similarly, within non-GCB DLBCL cohort, survival in group A was comparable to group B (HR 0.53, 95% CI 0.20-1.44, p = .21). We did not find an outcome difference between two commonly used salvage chemotherapy regimens in patients with PTF DLBCL based on COO.
Keyphrases
- diffuse large b cell lymphoma
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- high dose
- epstein barr virus
- prognostic factors
- stem cells
- randomized controlled trial
- acute myeloid leukemia
- cell therapy
- mesenchymal stem cells
- combination therapy
- free survival
- patient reported
- hodgkin lymphoma